How do healthcare professionals provide personalized care and support?
<Hepatology Digest>: How can caregivers provide personalized care and support to meet the specific needs of patients with MASLD?
Dr. LinghuaLi: Breakthrough on Hepatitis B Cure in HIV/HBV Co-Infected Patients
The 8th Asia-Pacific AIDS and Co-infection Conference (APACC 2023) was held in Singapore from June 8 to 10, 2023. During this conference, an oral presentation (Abstract #9) conducted by Dr. Linghua Li's team from the Eighth Affiliated Hospital, Guangzhou Medical University, China, attracted significant attention. Dr. Li 's team, based on the latest findings from a large cohort study, revealed that the hepatitis B surface antigen (HBsAg) clearance rate in HIV/HBV co-infected individuals who received long-term combination antiretroviral therapy (cART) could reach 8.1%. Furthermore, the research results unveiled that the main influencing factors for HBsAg clearance in HIV/HBV co-infected individuals included low baseline HBsAg levels, HBV genotype B, and a more than two-fold increase in ALT within six months of treatment.
Combination locoregional therapy with systemic therapy for intermediate and advanced stage HCC
<Hepatology Digest>: How does the combination locoregional therapy with systemic therapy improve the prognosis and survival rates for patients with intermediate and advanced stage HCC, and what are the synergistic effects…
The main mechanisms and strategies of HCC combination therapy
<Hepatology Digest>: What is the specific efficacy of combination therapies in improving tumor response in HCC, and how can the optimal treatment combinations and timing be determined?
The focus of scientific research in MASLD
<Hepatology Digest>: What are the current research focuses on metabolic-associated fatty liver disease? What are the key scientific questions that need further exploration?
Dr. LangBai: The Impact and Mechanism of TmPV1 Fungivirus on Talaromyces Marneffei Virulence
Over the years, significant progress has been made in the prevention and treatment of HIV/AIDS and co-infections. Society has provided the best medications and professional knowledge to combat HIV infections, making substantial contributions to those affected. From June 8th to 10th, 2023, the Asia-Pacific AIDS and Co-Infections Conference (APACC 2023) was held in Singapore. In this issue, we are honored to invite Dr. Lang Bai, Deputy Director of the Infectious Diseases Center, West China Hospital, Sichuan University, China, to share with us the latest research on Talaromyces marneffei infection, a common fungal disease among AIDS patients and other immunocompromised individuals in Southeast Asia.
Dr. Jennifer Hoy: How to Safely Transition ART in HIV Patients Achieving Viral Suppression?
Infectious Disease/HIV Specialist and Medical Professor at Monash University Alfred Hospital, Australia. Member of the Australian Antiretroviral Guidelines Committee and the International Antiviral Society-USA (IAS-USA) Antiretroviral Guidelines Panel. Leading and participating in the development of new antiretroviral drugs and the prevention and management of opportunistic infections, with a primary research focus on complications related to aging in HIV-infected individuals and their pathogenesis, prevention, and management.
What new concepts and methods have gut microbiome research brought to the diagnosis and treatment of autoimmune liver disease?
<Hepatology Digest>: How can studying the microbiome provide new insights and methods for the diagnosis, prevention, and treatment of autoimmune liver diseases?
How to improve HCV screening?
<Hepatology Digest>: Which populations should priority be given for HCV screening, and how can we improve screening rates to ensure early detection and treatment?